INNOVENT BIO (01801.HK): Q3 Product Revenue Exceeds RMB4.7bn, Up Over 40%

NewTimeSpace News: On 29 October 2026, Innovent Biologics, Inc. (stock code: 1801) published an inside information announcement that its product revenue for the third quarter of 2026 exceeded RMB4.7 billion, up more than 40% year on year, which the Company said confirms the momentum of its dual-engine strategy.

New products from its comprehensive pipeline—Xineryma® (mazdutide injection), Xibiluo® (tafolecimab injection) and Xibimin® (替妥尤单抗N01 injection)—continued to gain penetration, while several tyrosine kinase inhibitor (TKI) oncology products recorded rapid sales growth, driving the overall expansion of the commercial portfolio.

The Company is advancing three core assets into global Phase III development and expanding next-generation pipelines in oncology, cardiovascular and metabolic (CVM) diseases, autoimmune disease and ophthalmology. It currently has 41 pipeline candidates in clinical development and more than 100 early-stage programmes, with over 20 R&D collaborations with multinationals including Pfizer, Lilly, Takeda and Roche, of which five are co-development and co-commercialisation (Co-Co) programmes.

For 2030, the Company targets total revenue of RMB35 billion to RMB40 billion, first-tier pharmaceutical margins, at least five candidate molecules in global multicentre Phase III development, and product launches in major US and European markets. The announcement noted that the financial information is based on internal management records and has not been audited or reviewed by external auditors.